The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The promise of luspatercept for the treatment of lower-risk MDS
Valeria Santini, MD, University of Florence, Florence, Italy, discusses recent developments in the treatment of lower-risk myelodysplastic syndromes (LR-MDS), highlighting the promise of luspatercept, and further comments on ongoing trials evaluating this agent. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis, AbbVie, BMS, Gilead, Menarini, Geron, Otsuka: Honoraria.
